All News

Pharmaceutical Executive

GlaxoSmithKline (GSK) will invest £200 million ($327 million) to expand its manufacturing facilities in Ware, Hertfordshire and Worthing, Sussex in the United Kingdom and establish a new manufacturing innovation facility.

PHouston-author-pic_small1419938473285.gif

Pharmaceutical Executive

I find December a fairly schizophrenic month. Half of your head is thinking back to what you’ve achieved, half of your head is focussing forward to what you will do in the New Year. Looking back on 2013, I re-read Should CEOs use Social Media?, a post I wrote back in February encouraging pharma CEOs to show their faces on the social networks. Looking forward, I wonder if CEOs will actually do it in 2014?

Pharmaceutical Executive

At a time when burst bubbles have created uncertainty for investors in the biomedical realm, it’s smart for a drug company to make use of new legislation and emerging trends in venture capital. This is particularly true in spurring confidence in that translational area of drug development many deem the “Valley of Death”.

Medal_4mpix__MG_0199-150x150.png

Pharmaceutical Executive

The pursuit of excelMedal_4mpix__MG_0199-150x150lence in biopharmaceutical innovation in Russia has never had a sponsor-until now. Prix Galien International, a global network of Nobel laureates in medicines, established its 18th country beachhead in Moscow earlier this year, culminating in a historic first: an October 24 awards dinner to recognize the best in new drug research as well as innovation in biotechnology and pharmaceutical products.

pharmexectv-logo-829882-1408530978821.png

Pharmaceutical Executive

Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company?s new approach to drug development and its Phase III pipeline.

Pharmaceutical Executive

So, we’ve experienced two months of Obamacare. How is the U.S. pharmaceutical industry doing with this new program? I spent two weeks getting the opinions of several Rx representatives on their experience with Obamacare, as well as their thoughts on how it is impacting their marketing, sales, and R&D planning for 2014 and beyond.

W_Looney_blog_size.gif

Pharmaceutical Executive

New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry’s business model. In biopharma today, disruptive changes to the model are being driven by two forces.

Pharmaceutical Executive

The annual worldwide antibiotic awareness event - celebrated in Europe on November 15 - generated some alarming statistics, some reassuring statements from official sources, and some expressions of urgency from drug developers

PHouston-author-pic_small1419953549752.gif

Pharmaceutical Executive

There has been a lot of talk lately that ‘Big Data’ is just BS. Peter Houston looks beyond the hype to reveal what companies should be focusing on.

PHouston-author-pic_small.gif

Pharmaceutical Executive

As digital becomes a greater part of the pharma marketing mainstream, can the sector attract the digital marketing talent it needs to succeed in the space? That’s a question pondered this week by Rich Meyer on his World of DTC Marketing blog.

Pharmaceutical Executive

Big Pharma is quietly stepping up to provide critical supplies of essential medicines, other health equipment, and skilled local personnel to areas of the Philippines devastated by Typhoon Haiyan this month. Although industry operations in the Philippines appear largely intact, most companies are working through global humanitarian aid organizations due to the logistical challenges created by the collapse of infrastructure on the ground.

Pharmaceutical Executive

The future of healthcare centers on scale, population health and the value of care rather than the volume of care, according to thought leaders speaking at a leadership briefing in November in Akron, Ohio. But the political atmosphere also adds layers of complexity, they say.

EP_TopPipelineOrphans.png

Pharmaceutical Executive

Orphan drugs were given short shrift in PharmExec’s 2014 Pipeline Report, but a couple of pipeline candidates targeting small populations did make the list, and are expected to earn big dollars in the next few years.

Pharmaceutical Executive

Long awaited details have been announced in the Heads of Agreement for the latest Pharmaceutical Price Regulation Scheme (PPRS). It’s worth a read in full (and you can find it here) but some highlights are set out here.